Exsudative Age-Related Macular Degeneration Treatment Results in Patients Registered in the Nation-Wide AMADEUS Register
Authors:
O. Chrapek 1; Š. Pitrová 2; L. Dušek 3; J. Jarkovský 3; V. Kandrnal 3; J. Řehák 1
Authors‘ workplace:
Oční klinika FN a LF UP, Olomouc, přednosta doc. MUDr. Jiří Řehák, CSc., 2Oční klinika Nové Butovice, přednosta MUDr. Ján Lešták, CSc., MBA, 3Institut biostatistiky a analýz Masarykovy univerzity, Brno, přednosta doc. RNDr. Ladislav Dušek, Ph. D.
1
Published in:
Čes. a slov. Oftal., 66, 2010, No. 3, p. 110-118
Overview
The nation-wide register of patients with the exsudative age-related macular degeneration surveys the appearance and the success rate of the treatment of this disease in the Czech Republic. During the 12 months follow-up period of 38 patients treated with Macugen in monotherapy, receiving at least 7 injections of Macugen during one year period, we found the loss of less than 15 letters of the ETDRS chart in 62.2 % of treated eyes. During the 12 months follow-up period of 205 patients treated with Lucentis in monotherapy, receiving at least 3 injections of Lucentis, we found the loss of less than 15 letters of the EDTRS chart in 82.0 % of treated eyes. During the 12 months follow-up period of patients treated with Visudyne in monotherapy we found the loss of 15 letters of the EDRTS chart in 77.1 % of treated eyes.
Key words:
age-related macular degeneration (ARMD), ARMD treatment, AMADEUS registry
Sources
1. Boguszaková J.: Věkem podmíněná makulární degenerace. Prakt. Lék. 2001; 81: 310–314.
2. Bressler, N.M., Bressler, S. B., Fine, S.L.: Age related macular degeneration. Surv. Ophthalmol., 1988, 32, p. 357–412.
3. Brown DM, Kaiser PK, Michels M, et al.: for the ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 2006; 355: 14–26.
4. Ferrara N, Gerber H P, LeCouter J.: The biology of VEGF and its receptors. Nat. Med. 2003; 9: 669–676.
5. Gragoudas ES, Adamis AP, Cunningham Jr., et al.: Pegaptanib for Neovascular Age-Related Macular Degeneration. N. Engl. J. Med. 2004; 351: 2805–2816.
6. Gudelines for using Verteporfin in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update, Retina 2005; 25: 119–134.
7. Chrapek O, Řehák J.: Argon laserová fotokoagulace v terapii vlhké formy věkem podmíněné makulární degenerace. Čes. a slov. Oftal., 2004; 60: 45–53.
8. Philip J. Rosenfeld, M.D., Ph.D., et al. for the MARINA Study Group. Ranibizumab for Neovascular Age-Related Macular Degeneration N. Engl. J. Med. 2006; 355: 1419–1431.
9. Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration with Verteporfin. Two-Year Results of 2 Randomized Clinical Trials-TAP Report 2. Arch. Ophthalmol. 2001; 119: 198–207.
10. Querques, G., Azrya, S., Martinelli, D., et al. (2010). Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol 94: 292–296
11. Rosenfeld PJ, Brown DM, Heier JS, et al. for the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006; 355: 1–13.
12. Schmidt-Erfurth UM, Richard G, Augustin A, et al.: Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol. Scand. 2007; 85: 486–494.
13. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration with Verteporfin: one-year results of 2 randomized clinical trials – TAP report 1. Arch. Ophthalmol. 1999; 117: 1329–1345.
14. Treatment of Age-related Macular Degeneration With Photodynamic Therapy Study Group: Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration with Verteporfin. Two-Year Results of 2 Randomized Clinical Trials-TAP Report 2. Arch. Ophthalmol., 2001, 119, p. 198–207.
15. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 1508–1521.
Labels
OphthalmologyArticle was published in
Czech and Slovak Ophthalmology
2010 Issue 3
Most read in this issue
- Treatment of the Choroidal Neovascular Membrane by Ranibizumab (Lucentis): A Case Report
- Epidemiology of the Age-Related Macular Degeneration
- The Change of the anti-VEGF Agent in the Treatment of Exceptionally Active Choroidal Neovascular Membrane in Age-Related Macular Degeneration
- Photodynamic Therapy with Verteporfin: from Neovascularization to Hemangioma